ALGN vs TMDX
Align Technology vs TransMedics Group, Inc. — AI-powered side-by-side comparison
ALGN
Align Technology
73
Buy
VS
TMDX
TransMedics Group, Inc.
60
Buy
| Metric | ALGN | TMDX |
|---|
| AI Score |
73
|
60
|
| Price |
$172.86
|
$89.39
|
| P/E Ratio |
30.03×
|
20.22×
|
| ROE |
10.1%
|
40.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
66.5%
|
58.7%
|
| Debt / Equity |
0.03×
|
1.68×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
55.1
|
76.9
|
| Beta |
1.653
|
1.88
|
| Expected Upside |
+7.7%
|
—
|
AI Committee View
Current Innellis committee reasoning for ALGN versus TMDX.
ALGN leads by 13 points.
ALGN scores 73/100 (Buy) versus TMDX at 60/100 (Buy).
ALGN Committee View
100% agreement
5 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- Both daily and weekly trends are bearish — strong multi-timeframe downtrend.
TMDX Committee View
50% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 25.8% yoy -- genuine top-line momentum. Risk Analyst remains cautious — bollinger bandwidth of 26.6% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- ROE of 33.0% shows genuine earnings power backing the valuation — Value
- Revenue growing 25.8% YoY -- genuine top-line momentum — Growth
- EPS growing 105.5% YoY — Growth
Bear Case
- Price-to-book of 8.8x prices in significant intangible value — Value
- RSI at 77 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical